Article
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Gastroenterology - 1 Nov 2016
Gane Edward J, Kowdley Kris V, Pound David, Stedman Catherine A M, Davis Mitchell, Etzkorn Kyle, Gordon Stuart C, Bernstein David, Everson Gregory, Rodriguez-Torres Maribel, Tsai Naoky, Khalid Omer, Yang Jenny C, Lu Sophia, Dvory-Sobol Hadas, Stamm Luisa M, Brainard Diana M, McHutchison John G, Tong Myron, Chung Raymond T, Beavers Kimberly, Poulos John E, Kwo Paul Y, Nguyen Mindie H
Abstract excerpt
BACKGROUND & AIMS: Studies are needed to determine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 infections whose prior course of antiviral therapy has failed, and the feasibility of shortening treatment duration. We performed a phase 2 study to determine the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.